Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal [Yahoo! Finance]
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: Yahoo! Finance
Eli Lilly will pay UK-based MeiraGTx $75m upfront for global exclusive rights to AAV-AIPL1, a gene therapy in development for a rare form of inherited blindness, along with access to further gene therapy technologies developed by the biotech. The collaboration also includes more than $400m in milestone payments, as well as royalties on any drugs approved in the future. MeiraGTx's AAV-AIPL1 is in development to treat Leber congenital amaurosis type 4 (LCA4), a severe inherited retinal disease that is caused by genetic deficiency of aryl-hydrocarbon-interacting protein-like 1 (AIPL1). AIPL1 is a protein critical for the functioning of the eye's light-sensing pathway. AAV-AIPL1 has already produced positive results in a non-randomised study conducted in the UK, with results published in The Lancet in February 2025. Data from four of 11 children enrolled in the study, who had severe retinal dystrophy due to AIPL1 mutation, demonstrated that the therapy improved visual acuity in t
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- MeiraGTx (NASDAQ:MGTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- MeiraGTx (NASDAQ:MGTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx ConferencePR Newswire
- MeiraGTx (NASDAQ:MGTX) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- MeiraGTx Reports Third Quarter 2025 Financial and Operational ResultsGlobeNewswire
MGTX
Earnings
- 11/13/25 - Miss
MGTX
Sec Filings
- 11/24/25 - Form 4
- 11/13/25 - Form SCHEDULE
- 11/13/25 - Form 10-Q
- MGTX's page on the SEC website